A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC

计划入组 37 人 · 首次发布于 2026 年 8 月 21 日

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

计划入组 30 人 · 首次发布于 2019 年 10 月 30 日

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

计划入组 28 人 · 首次发布于 2018 年 12 月 24 日

squamous NSCLC vaccine

NSCLC (Antibody Therapeutics)

NANT Non-small Cell Lung Cancer Vaccine

Nuvalent

United States

Arvinas

United States

Veru Inc

United States

T-DXd-Pembrolizumab Combination Shows Promise in HER2-Positive NSCLC with 80% Response Rate in First-Line Setting

Zongertinib Shows Promise in HER2-Mutated NSCLC, Gains Breakthrough Therapy Designation

Trastuzumab Deruxtecan Shows Promise in HER2-Mutated NSCLC